Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin Versus Romidepsin Plus Pralatrexate in Relapsed or Refractory PTCL
NCT03355768Phase 3Withdrawn
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of pralatrexate in peripheral T-cell lymphoma (PTCL). Planned start Sep 2018; status: withdrawn.
02
Drugs
pralatrexate
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03355768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355768.